|
DGAP-News: Biotest AG
/ Key word(s): Market launch
10.06.2020 / 07:00
The issuer is solely responsible for the content of this announcement.
PRESS RELEASE
Biotest successfully enters China, the world's biggest Human Albumin market
- First sales of Human Albumin in China
- Access to the largest Human Albumin market with more than 450 tonnes per year representing a market value of about € 2.5 billion
- Chinese market has double-digit growth rates every year
Dreieich, 10 June 2020. Biotest achieves a major milestone in its international expansion strategy by recording first ever company sales of Human Albumin in China during the month of June.
Human Albumin is used for stabilisation of blood circulation in severe diseases such as burns as well as chronic diseases of the liver and kidneys or complications associated with protein loss.
China represents not only the biggest Human Albumin market in the world in terms of volume with more than 450 tonnes per year but also the biggest in terms of value with a market value of about € 2.5 billion. In addition, the annual consumption has been growing with double-digit numbers during the last years.
Biotest together with its distributor Anhui Tonrol Pharmaceutical Co. Ltd is now present in the world largest Human Albumin market with its product "Human Albumin Injection".
"China and the Asia Pacific region as a whole represent the main pillars of Biotest international expansion. We are very proud to enter successfully in a market with many opportunities. Together with our partner we have worked successfully with the Chinese authorities despite the difficult COVID-19 situation and proved to be a reliable and energetic partner for all our stakeholders" commented Giuliano Tagliabue, Vice President Region Intercontinental.
China represents a crucial expansion of Biotest's Human Albumin. Licensed in more than 48 countries and with a rising demand for human albumin, Biotest plans to double production capacity as part of the "Biotest Next Level" expansion programme at the Dreieich site.
About Human Albumin
Albumin is used in particular in intensive care medicine and acute care. Patients with extensive blood or fluid loss, due to burns among other things, have too little of the important proteins in their blood. This protein loss is compensated by administering Albumin. Albumin is also used for volume replacement in cases of blood poisoning. Unlike synthetically manufactured drugs, Albumin produced from human plasma offers particularly good tolerability. It is also the most important protein carrier in the blood for binding and removing (harmful) substances from the vascular system.
Albumin is commercialized in Germany under the brand name "Albiomin" and in China marketed as "Human Albumin Injection".
About Biotest
Biotest is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive care medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumin based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. Biotest has more than 1,800 employees worldwide. The ordinary and preference shares of Biotest AG are listed in the Prime Standard on the German stock exchange.
IR contact
Dr Monika Buttkereit
Phone: +49-6103-801-4406
Mail: investor_relations@biotest.de
PR contact
Dirk Neumüller
Phone: +49-6103-801-269
Mail: pr@biotest.com
Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.com
Ordinary shares: securities' ID No. 522720; ISIN DE0005227201
Preference shares: securities' ID No. 522723; ISIN DE0005227235
Listing: Frankfurt (Prime Standard)
Open Market: Berlin, Düsseldorf, Hamburg/ Hanover, Munich, Stuttgart, Tradegate
Disclaimer
This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.
10.06.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de
|
